NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were payable to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its Board of Directors has authorized a share repurchase plan on Tuesday, September 19th 2017, which allows the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 6.3% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) released its quarterly earnings results on Monday, August, 6th. The company reported $1.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.03. The firm earned $3.33 billion during the quarter, compared to the consensus estimate of $3.31 billion. Henry Schein had a net margin of 3.15% and a return on equity of 20.40%. Henry Schein's revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company posted $0.88 EPS. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Monday, November, 5th 2018. View Earnings Estimates for Henry Schein.

Henry Schein updated its FY18 earnings guidance on Monday, August, 6th. The company provided EPS guidance of $4.06-4.14 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.11.

19 analysts have issued 1 year price objectives for Henry Schein's stock. Their forecasts range from $73.00 to $102.00. On average, they expect Henry Schein's share price to reach $84.00 in the next twelve months. This suggests a possible upside of 2.5% from the stock's current price. View Analyst Price Targets for Henry Schein.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein.

Some companies that are related to Henry Schein include Express Scripts (ESRX), Illumina (ILMN), Boston Scientific (BSX), HCA Healthcare (HCA), Vertex Pharmaceuticals (VRTX), Humana (HUM), Zoetis (ZTS), FRESENIUS SE &/S (FSNUY), BEXIMCO PHARMAC/S GDR REGS (BXP), Regeneron Pharmaceuticals (REGN), Baxter International (BAX), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), ESSILOR Intl S/S (ESLOY) and Actelion (ALIOF).

News stories about HSIC stock have been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Henry Schein earned a news impact score of 0.16 on Accern's scale. They also gave headlines about the company an impact score of 45.51 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Henry Schein.

Henry Schein's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Longview Partners Guernsey LTD (8.99%), BlackRock Inc. (7.02%), Select Equity Group L.P. (4.35%), FMR LLC (4.33%), Janus Henderson Group PLC (2.08%) and American Century Companies Inc. (1.42%). Company insiders that own Henry Schein stock include Barry J Alperin, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

HSIC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Fisher Asset Management LLC, PGGM Investments, Legal & General Group Plc, Swedbank, Meadow Creek Investment Management LLC, First Trust Advisors LP and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Henry Schein company stock in the last year include Barry J Alperin, Mark E Mlotek, Paul Brons and Paul Rose. View Insider Buying and Selling for Henry Schein.

HSIC stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., American Century Companies Inc., Glenmede Trust Co. NA, Janus Henderson Group PLC, Select Equity Group L.P., Canada Pension Plan Investment Board and Jane Street Group LLC. View Insider Buying and Selling for Henry Schein.

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HSIC stock can currently be purchased for approximately $81.96.

Henry Schein has a market capitalization of $12.30 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe.

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected]